Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis
Harlan F. Weisman(Johns Hopkins University), Douglas T. Fearon(Cornell University), Michael F. Concino(One Cell Systems (United States)), Myron L. Weisfeldt(Johns Hopkins University), Henry C. Marsh(One Cell Systems (United States)), Michael Boyle(McMaster University), Kenneth H. Roux(Florida State University), Gerald Carson(One Cell Systems (United States)), Michelle K. Leppo(Johns Hopkins University)
Cited by 979
Related Papers
Update on Key Emerging Challenges in Cystic Fibrosis
|Medical Principles and Practice|2014|3.7k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Multiattribute and Single-Attribute Utility Functions for the Health Utilities Index Mark 3 System
|Medical Care|2002|1.3k
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
|Nature|2017|1.2k
Inflammatory subtypes in asthma: Assessment and identification using induced sputum
|Respirology|2006|939